Returning guest, Dr. Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda discusses the news that Takeda’s dengue vaccine candidate, TAK-003, was recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the prevention of dengue disease caused by any serotype in individuals four years of age and older in Europe and in dengue-endemic countries which participated in the EU-M4all procedure. The news follows the vaccine’s first approval in Indonesia.
Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, he leads the global program team in the development of Takeda’s dengue vaccine, QDENGA ® (TAK-003). Dr. Wallace joined Takeda in September 2013 as Global Program Medical Director.
Dr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, he held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Dr. Wallace served as clinical team leader for Sanofi’s dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women’s health.
Dr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.